'Off-the-Shelf' Therapy Active after CAR T-cell Failure

]]>(MedPage Today) -- ORLANDO--Half of patients with relapsed, difficult-t0-treat non-Hodgkin lymphoma (NHL) responded to an investigational bispecific antibody, including patients resistant or refractory to CAR T-cell therapy, data from a large...